Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 4/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | TSPO | P30536 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20810200 | 0.93 | PPARD (0.41) | P2RY14PPARDTSPOCYP2C9TMEM97 | |
| SCHEMBL20810056 | 0.92 | NPC1 (0.46) | ALDH1A1MAPT | |
| SCHEMBL20810062 | 0.91 | SMN1; SMN2 (0.47) | CYP2C9ALDH1A1MAPT | |
| SCHEMBL20810198 | 0.91 | MAPT (0.42) | P2RY14PPARDALDH1A1MAPTALKBH5 | |
| SCHEMBL20810199 | 0.91 | MAPT (0.53) | ALDH1A1MAPTTDP1 | |
| SCHEMBL20810197 | 0.90 | MAPT (0.41) | PPARDALDH1A1MAPTALKBH5 | |
| SCHEMBL20810053 | 0.89 | SMN1; SMN2 (0.50) | CYP2C9ALDH1A1MAPTTDP1 | |
| SCHEMBL20809999 | 0.84 | LMNA (0.46) | P2RY14PPARDTSPOCYP2C9TMEM97 | |
| SCHEMBL20810149 | 0.83 | TDP1 (0.51) | P2RY14PPARDTSPOCYP2C9TMEM97 | |
| SCHEMBL20810054 | 0.82 | TDP1 (0.49) | PPARDMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077777-A1 | NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF | XIAMEN INSTITUTE OF RARE EARTH MATERIALS (CN) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077777-A1 | NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR3, NAPRT | P2RY14 3635/4885PPARD 3049/4885TSPO 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.